公开(公告)号：USRE42324E1

公开(公告)日：2011-05-03

申请号：US12757821

申请日：2010-04-09

申请人： Sylvia Laffer ,  Erik Hogbom ,  Kenneth H. Roux ,  Jonas Adriansson ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft ,  Hans Grönlund ,  Rudolf Valenta

发明人： Sylvia Laffer ,  Erik Hogbom ,  Kenneth H. Roux ,  Jonas Adriansson ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft ,  Hans Grönlund ,  Rudolf Valenta

IPC分类号： A61K39/395 ,  C12P21/08 ,  C07K16/42 ,  C07K19/00

CPC分类号： C07K16/16 ,  A61K2039/505 ,  C07K16/4291 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76

摘要： The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma.The invention provides a Fab (antibody fragment), having the following characteristics: a) inhibits the IgE-FcεRI interaction; b) binds to free and cell-bound IgE; and c) is non-anaphylactic.

摘要翻译： 本发明涉及一种具有普遍治疗过敏和哮喘潜力的新型候选药物。 本发明提供具有以下特征的Fab（抗体片段）：a）抑制IgE-Fc和RI的相互作用; b）结合游离和细胞结合的IgE; 和c）是非过敏性的。

公开(公告)号：US06986889B2

公开(公告)日：2006-01-17

申请号：US10108301

申请日：2002-03-28

申请人： Sylvia Laffer ,  Erik Högbom ,  Kenneth H. Roux ,  Jonas Adriansson ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft ,  Hans Grönlund ,  Rudolf Valenta

发明人： Sylvia Laffer ,  Erik Högbom ,  Kenneth H. Roux ,  Jonas Adriansson ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft ,  Hans Grönlund ,  Rudolf Valenta

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K16/46 ,  C12P21/08

CPC分类号： C07K16/16 ,  A61K2039/505 ,  C07K16/4291 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76

摘要： The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma.The invention provides a Fab (antibody fragment), having the following characteristics: a) inhibits the IgE-FcεRI interaction; b) binds to free and cell-bound IgE; and c) is non-anaphylactic.

摘要翻译： 本发明涉及一种具有普遍治疗过敏和哮喘潜力的新型候选药物。 本发明提供具有以下特征的Fab（抗体片段）：a）抑制IgE-FcepsilonRI相互作用; b）结合游离和细胞结合的IgE; 和c）是非过敏性的。

公开(公告)号：US07482009B2

公开(公告)日：2009-01-27

申请号：US10142049

申请日：2002-05-10

申请人： Rudolf Valenta ,  Susanne Vrtala ,  Sabine Stummfoll ,  Hans Grönlund ,  Monika Grote ,  Luca Vangelista ,  Annalisa Pastore ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft

发明人： Rudolf Valenta ,  Susanne Vrtala ,  Sabine Stummfoll ,  Hans Grönlund ,  Monika Grote ,  Luca Vangelista ,  Annalisa Pastore ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft

IPC分类号： A61K39/00 ,  A61K39/35 ,  A61K39/36 ,  A61K38/00 ,  A01N37/18

CPC分类号： C07K14/415 ,  A61K38/00 ,  A61K39/00 ,  A61K39/36 ,  Y10S424/805 ,  Y10S424/81 ,  Y10S530/806 ,  Y10S530/868

摘要： The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.

摘要翻译： 本发明涉及衍生自Phlp6变应原的低变应原性免疫原性分子，其中Ph1p6分子具有N-末端和/或C-末端缺失，其使该分子至少基本上缺少IgE结合能力。 本发明还涉及来自Phlp6变应原的分子的低变应原性免疫原性组合，其包含（i）具有N-末端缺失的Ph1p6分子，其使得该分子至少基本上不具有IgE结合能力，和（ii） 具有C末端缺失的Phl p6分子，其使得该分子至少基本上缺少IgE结合能力，该两个分子一起包含Phlp6的完整序列。本发明还涉及低变应原性免疫原性分子或分子 低敏感和诊断中的混合物。

公开(公告)号：US08440200B2

公开(公告)日：2013-05-14

申请号：US11933498

申请日：2007-11-01

申请人： Rudolf Valenta ,  Susanne Vrtala ,  Sabine Stumvoll ,  Hans Grönlund ,  Monika Grote ,  Luca Vangelista ,  Annalisa Pastore ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft

发明人： Rudolf Valenta ,  Susanne Vrtala ,  Sabine Stumvoll ,  Hans Grönlund ,  Monika Grote ,  Luca Vangelista ,  Annalisa Pastore ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft

IPC分类号： A61K39/00 ,  A61K39/35 ,  A61K39/36 ,  A61K38/00

CPC分类号： C07K14/415 ,  A61K38/00 ,  A61K39/00 ,  A61K39/36 ,  Y10S424/805 ,  Y10S424/81 ,  Y10S530/806 ,  Y10S530/868

摘要： Methods for desensitization of a mammal suffering from IgE mediated allergy comprise the steps of: administering to said mammal a therapeutically effective amount of an immunogenic and hypoallergenic composition which comprises (i) a Phl p 6 molecule having an N-terminal truncation which makes the molecule at least lack IgE binding capacity, and/or (ii) a Phl p 6 molecule having a C-terminal truncation which makes the molecule at least lack IgE binding capacity, wherein the molecules of (i) and (ii), if employed in combination, together span the complete sequence of Phl p 6, and a pharmaceutically acceptable carrier.

摘要翻译： 对患有IgE介导的过敏的哺乳动物脱敏的方法包括以下步骤：向所述哺乳动物施用治疗有效量的免疫原性和低变应原性组合物，其包含（i）具有N端截短的Ph1p6分子，其使得分子 至少缺乏IgE结合能力，和/或（ii）具有C末端截短的Ph1p6分子，其使得该分子至少缺乏IgE结合能力，其中（i）和（ii）的分子如果用于 组合，一起跨越Phlp6的完整序列和药学上可接受的载体。

公开(公告)号：US06572859B1

公开(公告)日：2003-06-03

申请号：US09696169

申请日：2000-10-26

申请人： Rudolf Valenta ,  Susanne Vrtala ,  Sabine Stummfoll ,  Hans Grönlund ,  Monika Grote ,  Luca Vangelista ,  Annalisa Pastore ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft

发明人： Rudolf Valenta ,  Susanne Vrtala ,  Sabine Stummfoll ,  Hans Grönlund ,  Monika Grote ,  Luca Vangelista ,  Annalisa Pastore ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft

IPC分类号： A61K3935

CPC分类号： C07K14/415 ,  A61K38/00 ,  A61K39/00 ,  A61K39/36 ,  Y10S424/805 ,  Y10S424/81 ,  Y10S530/806 ,  Y10S530/868

摘要： The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.

公开(公告)号：US07482010B2

公开(公告)日：2009-01-27

申请号：US10305238

申请日：2002-11-27

申请人： Rudolf Valenta ,  Susanne Vrtala ,  Sabine Stummfoll ,  Hans Grönlund ,  Monika Grote ,  Luca Vangelista ,  Annalisa Pastore ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft

发明人： Rudolf Valenta ,  Susanne Vrtala ,  Sabine Stummfoll ,  Hans Grönlund ,  Monika Grote ,  Luca Vangelista ,  Annalisa Pastore ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft

IPC分类号： A61K39/00

CPC分类号： C07K14/415 ,  A61K38/00 ,  A61K39/00 ,  A61K39/36 ,  Y10S424/805 ,  Y10S424/81 ,  Y10S530/806 ,  Y10S530/868

摘要： The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p 6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.

摘要翻译： 本发明涉及衍生自Phlp6变应原的低变应原性免疫原性分子，其中Ph1p6分子具有至少基本上缺乏IgE结合能力的N-末端和/或C-末端缺失。 本发明还涉及来自Phlp6变应原的分子的低变应原性免疫原性组合，其包含（i）具有N-末端缺失的Ph1p6分子，其使得该分子至少基本上不具有IgE结合能力，和（ii） 具有C末端缺失的Phl p6分子，其使得该分子至少基本上缺少IgE结合能力，该两个分子一起包含Phlp6的完整序列。本发明还涉及低变应原性免疫原性分子或分子 低敏感和诊断中的混合物。

公开(公告)号：US07108858B2

公开(公告)日：2006-09-19

申请号：US09897042

申请日：2001-07-03

申请人： Rudolf Valenta ,  Susanne Vrtala ,  Luca Vangelista ,  Hans-Georg Eichler ,  Wolfgang R. Sperr ,  Peter Valent ,  Christof Ebner ,  Dietrich Kraft ,  Hans Grönlund

发明人： Rudolf Valenta ,  Susanne Vrtala ,  Luca Vangelista ,  Hans-Georg Eichler ,  Wolfgang R. Sperr ,  Peter Valent ,  Christof Ebner ,  Dietrich Kraft ,  Hans Grönlund

IPC分类号： A61K39/395

CPC分类号： C07K16/16 ,  A61K39/00 ,  C07K14/415 ,  Y10S530/868

摘要： The present invention is drawn to an immunogen derived from a protein allergen, which is a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen which contains an IgG epitope partly but not wholly overlapping an IgE epitope of the protein allergen; b) a polymeric form of the fragment, in which the fragment constitutes the monomeric units; or c) a non-anaphylactic recombinant polymeric form of the protein allergen having 2–10 monomeric units, in which the protein allergen constitutes the monomeric units. The present invention is further drawn to the use of the immunogen for in vitro diagnoses of type I allergy and hyposensitization.

摘要翻译： 本发明涉及来自蛋白质变应原的免疫原，其是a）蛋白质变应原的非过敏性免疫原性重组片段，其含有部分但不完全重叠蛋白质变应原的IgE抗原决定簇的IgG表位; b）片段的聚合形式，其中片段构成单体单元; 或c）具有2-10个单体单元的蛋白质变应原的非过敏重组聚合形式，其中蛋白质变应原构成单体单元。 本发明进一步涉及免疫原用于I型过敏和过敏反应的体外诊断的用途。

公开(公告)号：US07244431B2

公开(公告)日：2007-07-17

申请号：US10026911

申请日：2001-12-27

申请人： Margarete Focke ,  Vera Mahler ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft ,  Rudolf Valenta

发明人： Margarete Focke ,  Vera Mahler ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft ,  Rudolf Valenta

IPC分类号： A61K39/00

CPC分类号： A61K39/35 ,  A61K39/36 ,  C07K14/415 ,  Y10S424/81 ,  Y10S530/868

摘要： The present invention relates to a pharmaceutical composition containing a peptide and a pharmaceutically acceptable carrier or diluent wherein the peptide has a length of 8 to 50 amino acids, at least three preferably consecutive amino acids of the peptide are identical to at least three amino acids which appear in close vicinity on the molecular surface of an allergenic protein, and said at least three amino acids are solvent-exposed amino acids in the allergenic protein. The invention also concerns a method for the preparation of the pharmaceutical composition.

摘要翻译： 本发明涉及含有肽和药学上可接受的载体或稀释剂的药物组合物，其中该肽具有8至50个氨基酸的长度，该肽的至少3个优选连续的氨基酸与至少3个氨基酸相同， 出现在过敏原蛋白的分子表面附近，并且所述至少三个氨基酸是过敏原蛋白质中的溶剂暴露的氨基酸。 本发明还涉及制备药物组合物的方法。

公开(公告)号：US20090017051A1

公开(公告)日：2009-01-15

申请号：US11711741

申请日：2007-02-28

申请人： Margarete Focke ,  Vera Mahler ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft ,  Rudolf Valenta

发明人： Margarete Focke ,  Vera Mahler ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft ,  Rudolf Valenta

IPC分类号： A61K39/35 ,  G01N33/566 ,  A61K39/36 ,  A61P37/08

CPC分类号： A61K39/35 ,  A61K39/36 ,  C07K14/415 ,  Y10S424/81 ,  Y10S530/868

摘要： The present invention relates to a pharmaceutical composition containing a peptide and a pharmaceutically acceptable carrier or diluent wherein the peptide has a length of 8 to 50 amino acids, at least three preferably consecutive amino acids of the peptide are identical to at least three amino acids which appear in close vicinity on the molecular surface of an allergenic protein, and said at least three amino acids are solvent-exposed amino acids in the allergenic protein. The invention also concerns a method for the preparation of the pharmaceutical composition.

摘要翻译： 本发明涉及含有肽和药学上可接受的载体或稀释剂的药物组合物，其中该肽具有8至50个氨基酸的长度，该肽的至少3个优选连续的氨基酸与至少3个氨基酸相同， 出现在过敏原蛋白的分子表面附近，并且所述至少三个氨基酸是过敏原蛋白质中的溶剂暴露的氨基酸。 本发明还涉及制备药物组合物的方法。

公开(公告)号：US20080160038A1

公开(公告)日：2008-07-03

申请号：US11933498

申请日：2007-11-01

申请人： Rudolf Valenta ,  Susanne Vrtala ,  Sabine Stumvoll ,  Hans Gronlund ,  Monika Grote ,  Luca Vangelista ,  Annalisa Pastore ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft

发明人： Rudolf Valenta ,  Susanne Vrtala ,  Sabine Stumvoll ,  Hans Gronlund ,  Monika Grote ,  Luca Vangelista ,  Annalisa Pastore ,  Wolfgang R. Sperr ,  Peter Valent ,  Dietrich Kraft

IPC分类号： A61K39/35

CPC分类号： C07K14/415 ,  A61K38/00 ,  A61K39/00 ,  A61K39/36 ,  Y10S424/805 ,  Y10S424/81 ,  Y10S530/806 ,  Y10S530/868

摘要： Methods for desensitization of a mammal suffering from IgE mediated allergy comprise the steps of: administering to said mammal a therapeutically effective amount of an immunogenic and hypoallergenic composition which comprises (i) a Phi p 6 molecule having an N-terminal truncation which makes the molecule at least lack IgE binding capacity, and/or (ii) a Phi p 6 molecule having a C-terminal truncation which makes the molecule at least lack IgE binding capacity, wherein the molecules of (i) and (ii), if employed in combination, together span the complete sequence of Phl p 6, and a pharmaceutically acceptable carrier.

摘要翻译： 对患有IgE介导的过敏的哺乳动物进行脱敏的方法包括以下步骤：向所述哺乳动物施用治疗有效量的免疫原性和低变应原性组合物，其包含（i）具有N末端截短的Phi 6分子，其使得该分子 至少缺乏IgE结合能力，和/或（ii）具有C末端截短的PhiP 6分子，其使得该分子至少缺乏IgE结合能力，其中（i）和（ii）的分子如果用于 组合，一起跨越Phlp6的完整序列和药学上可接受的载体。